GUSTO V 2002

A randomised clinical trial investigating the effect of Abciximab versus in

1 Treatments

<table>
<thead>
<tr>
<th>Studied treatment</th>
<th>Abciximab + half-dose reteplace bolus (0.25 mg/kg) followed by 12-hour infusion (0.125 ìg/kg per min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control treatment</td>
<td>full-dose reteplase</td>
</tr>
</tbody>
</table>

Concomittant treatments -

2 Patients

Patients -

Inclusion criteria -

Exclusion criteria -

3 Methods

Blinding -

Design -

Centers -

Geographical area -

Sample size 16588 ( 8328 / 8260 )

ArretTrt1 -

ArretTrt0 -

PeriodeInclusion 1999-2001

Hypothese -

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>reinfarctus</td>
<td>192/8328</td>
<td>289/8260</td>
<td>0.66</td>
<td>[0.55; 0.79]</td>
</tr>
<tr>
<td>30-Day Mortality</td>
<td>468/8328</td>
<td>488/8260</td>
<td>0.95</td>
<td>[0.83; 1.08]</td>
</tr>
<tr>
<td>Long-Term (6- and 12-Month) Mortality</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>
5 References

6 Comments